← Search & browse all drugs
CARDIOVASCULAR SYSTEM › BETA BLOCKING AGENTS › BETA BLOCKING AGENTS AND THIAZIDES › Beta blocking agents, non-selective, and thiazides
metipranolol and thiazides, combinations
C07BA68
Forms & Strengths
- Ophthalmic solution: metipranolol 0.3% combined with thiazide diuretic formulations (regional availability varies)
Adult Dosing
- Ophthalmic: Instill 1 drop into the affected eye(s) twice daily
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Reduction of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma
Mechanism of Action
- Metipranolol is a non-selective beta-adrenergic receptor blocking agent that reduces aqueous humor production; thiazide combinations may provide supplementary systemic or local ocular effects depending on the specific formulation
Contraindications
- Bronchial asthma
- History of bronchospasm or severe chronic obstructive pulmonary disease
- Sinus bradycardia
- Second- or third-degree atrioventricular block
- Overt cardiac failure
- Cardiogenic shock
- Hypersensitivity to beta-blockers, thiazides, or sulfonamide-derived drugs
Adverse Reactions
- Transient ocular burning or stinging
- Blurred vision
- Conjunctivitis
- Bradycardia
- Hypotension
- Bronchospasm
- Fatigue
- Electrolyte disturbances (hypokalemia, hyponatremia due to thiazide component)
Drug Interactions
- Systemic beta-blockers may result in additive beta-blocking effects and systemic toxicity
- Calcium channel blockers or digitalis glycosides may cause additive effects on AV conduction and bradycardia
- Catecholamine-depleting drugs (e.g., reserpine) may produce hypotension and marked bradycardia
- Thiazide components may increase the risk of lithium toxicity and alter glycemic control with antidiabetic agents
Curated Content: Needs Vetting Before Put to Clinical Use